Centre for Drug Design & Discovery (CD3)
CD3 is a drug discovery center and investment fund based in Leuven, Belgium, focusing on transforming innovative biomedical research into new medicines. It collaborates with academic institutes and biotech/pharma partners, providing expertise, infrastructure, and funding to develop potential new drugs. Its mission is to discover medicines that address serious medical needs through partnerships, investments, and co-creation of new drugs.
Industries
Nr. of Employees
small (1-50)
Centre for Drug Design & Discovery (CD3)
Products
RSV antivirals
Project developing antiviral molecules targeting respiratory syncytial virus (RSV).
Dengue virus inhibitors
Project focused on discovery of inhibitors active against dengue virus.
Yap/TAZ-TEAD inhibitors
Project developing inhibitors targeting the Yap/TAZ-TEAD pathway for hippo-dependent cancers.
MALT1 inhibitors
Project focused on discovery of MALT1 inhibitors for autoimmune and inflammatory diseases.
Influenza virus inhibitors
Project developing inhibitor molecules active against influenza viruses.
HRV (human rhinovirus) inhibitors
Project focused on discovery of inhibitors targeting human rhinovirus.
RSV antivirals
Project developing antiviral molecules targeting respiratory syncytial virus (RSV).
Dengue virus inhibitors
Project focused on discovery of inhibitors active against dengue virus.
Yap/TAZ-TEAD inhibitors
Project developing inhibitors targeting the Yap/TAZ-TEAD pathway for hippo-dependent cancers.
MALT1 inhibitors
Project focused on discovery of MALT1 inhibitors for autoimmune and inflammatory diseases.
Influenza virus inhibitors
Project developing inhibitor molecules active against influenza viruses.
HRV (human rhinovirus) inhibitors
Project focused on discovery of inhibitors targeting human rhinovirus.
Services
Provides capital and investment management for drug discovery start-ups, spin-offs and biotech companies and co-invests in collaborative projects.
Project-based collaborations with academic research groups and small companies to jointly discover and advance potential medicines.
Provides HTS workflows and associated automation to identify active compounds against biological targets.
Access to a viral sample repository to support antiviral research and assay development.
Facilitates licensing or partnering of discovered molecules to pharmaceutical companies for further development.
Provides capital and investment management for drug discovery start-ups, spin-offs and biotech companies and co-invests in collaborative projects.
Project-based collaborations with academic research groups and small companies to jointly discover and advance potential medicines.
Provides HTS workflows and associated automation to identify active compounds against biological targets.
Access to a viral sample repository to support antiviral research and assay development.
Facilitates licensing or partnering of discovered molecules to pharmaceutical companies for further development.
Expertise Areas
- Translational drug discovery
- High-throughput screening and hit discovery
- Antiviral drug discovery
- Oncology drug discovery
Key Technologies
- High-throughput screening (HTS)
- Virus biobank / sample repository
- Automated screening robotics
- Assay development for target-based screens
News & Updates
Enedra Therapeutics secured funding to develop therapies for difficult-to-treat cancers.
Memorial for Harrold van Barlingen.
Collaboration to develop therapies for Parkinson's disease.
Scientific publication on coronavirus particle assembly as a drug target.
Collaboration with SandboxAQ and KU Leuven to identify new Parkinson’s treatments.
Prof. Lieve Naesens and CD3 receive funding to prepare for influenza pandemics.
Enedra Therapeutics secured funding to develop therapies for difficult-to-treat cancers.
Memorial for Harrold van Barlingen.
Collaboration to develop therapies for Parkinson's disease.
Scientific publication on coronavirus particle assembly as a drug target.
Collaboration with SandboxAQ and KU Leuven to identify new Parkinson’s treatments.
Prof. Lieve Naesens and CD3 receive funding to prepare for influenza pandemics.